BEAM-201

N/A

Report date: 2023/06/06 20:00:40

Base Information

Drug NameBEAM-201
Drug Alias NameBEAM-201
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Gene editing > Base editing
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityT-cell antigen CD7 inhibitors
TargetsT-cell antigen CD7
Therapy Area/IndicationsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, T-Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBeam Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBeam Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, T-Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A